TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00413400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: 50 mg one syringe sc 2X per week for three months followed by 50 mg one syringe sc 1X per week for three months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg one syringe sc 2x per week for three months followed by 50 mg one syringe sc 1X per week for three months
Study: NCT01297556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy(CBT)
Description: Cognitive Behavior Therapy(CBT) for 6 weeks.
Study: NCT03905408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mL of 50% Glucose
Description: 1st dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mL of 50% Glucose
Description: 2nd dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mL of 50% Glucose
Description: 3rd dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mL of 50% Glucose
Description: 4th dose
Study: NCT00121381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus plus topical corticosteroid (TCS)
Description: Pimecrolimus 1 % cream plus topical corticosteroid (TCS) twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
Description: twice daily administration
Study: NCT01748266

Intervention type: OTHER
Intervention: microcirculatory reactivity
Description: Microcirculation of the thenar eminence was analyzed by NIRS technology, through the StO2 and the resaturation slope after an ischemic challenge.
Study: NCT03319173

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: Subjects in the experimental group will receive clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation.~Subjects in the control group will follow the their current dietary protocol (Standard American Diet-SAD).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Subjects in the experimental group will receive clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation.~Subjects in the control group will follow the their current dietary protocol (Standard American Diet-SAD).
Study: NCT00522015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rivastigmine
Description: rivastigmine 6 mg up to 12 mg daily; Taken in two doses from 3 mg to 6 mg Rivastigmine twice a day
Study: NCT03507231

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Email Message
Description: Participants will randomly receive an e-mail message about the availability of free flu vaccines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email Message
Description: Participants will randomly receive an e-mail message about the availability of free flu vaccines.
Study: NCT03381924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational programme
Description: In each session, neuroscience-based information on the neurophysiology of pain and migraine were provided with audio-visual support.
Study: NCT03507231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email Message
Description: Participants will randomly receive an e-mail message about the availability of free flu vaccines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive for Vaccination
Description: $5 gift card offered for vaccination

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive for completing a short survey
Description: $5 gift card offered for completing s short survey after one gets vaccinated
Study: NCT03428932

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed Loop (Medtronic 670G)
Description: A loaner Medtronic 670G insulin pump, Enlite 3 sensor and GST3C Guardian transmitter will be utilized

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Subjects will continue on their current treatment (insulin pump or injections), with follow up every 3 months.
Study: NCT04027543

Intervention type: COMBINATION_PRODUCT
Intervention: Neoadjuvant chemoradiotherapy
Description: In most patients, the chemotherapy regimens before surgery were consisted of cisplatin combined with either fluorouracil or taxanes.

Intervention type: PROCEDURE
Intervention: Oesophagectomy
Description: Various surgical oesophagectomy methods were used, such as Ivor Lewis, transthoracic, three-hole, transhiatal, and left transthoracic,and the appropriate surgical approach for each patient was chosen according to the tumour location, size, and depth.

Intervention type: DRUG
Intervention: Neoadjuvant chemotherapy
Description: In most patients, the chemotherapy regimens before surgery were consisted of cisplatin combined with either fluorouracil or taxanes.
Study: NCT03652168

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: 10 minute a day, 8 week digital meditation
Study: NCT01754870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance
Study: NCT00074269

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: graft-versus-tumor induction therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT02633605

Intervention type: DEVICE
Intervention: First Sense Medical®
Study: NCT01509092

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vitrectomy surgery
Description: pars plana vitrectomy +internal limiting membrane peeling done immediately after the identification of the macular hole
Study: NCT03803995

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mapping and Pacing the His Bundle
Description: During the device implant procedure, 3D electro-anatomical mapping of the His Bundle region will be performed using EnSite™ Precision™ mapping system and Advisor™ HD Grid mapping catheter. This procedure might be part of the standard-of-care at the participating centers.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Placing a guidewire in Coronary sinus for measurement of Q-LV during His Bundle pacing or, if needed, for LV pacing
Description: During the device implant procedure, a VisionWire coronary guidewire will also be placed into a branch of coronary sinus (CS), targeting a lateral branch. This guidewire could be used for collecting local left ventricle (LV) activation time (Q-LV) or pacing the LV. This guidewire could also be used to deliver a LV lead at physician's discretion. This procedure might be part of the standard-of-care at the participating centers.
Study: NCT04227990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Pegfilgrastim is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, doxorubicin, and cyclophosphamide (TAC)
Description: Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, doxorubicin, and cyclophosphamide (TAC)
Description: Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel, doxorubicin, and cyclophosphamide (TAC)
Description: Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.
Study: NCT03381924

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine clinical practice
Description: Patients allocated to the control group will only receive the drugs used in the habitual clinical practice
Study: NCT01228071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone gel 2%
Description: 40 mg testosterone gel 2%
Study: NCT04140708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise--Rock Steady Boxing class
Description: Rock Steady Boxing is a class designed specifically for those with Parkinsonism and movement difficulty using explosive and fine tuned movements as well as cognitive learning skills.
Study: NCT00924976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Steps for Achieving Financial Empowerment (SAFE)
Description: The SAFE is a brief, 5-component intervention that aims to facilitate a cooperative consumer-payee relationship, increase accurate knowledge about representative payeeship, promote collaborative money management and effective budgeting, and prepare mutually developed plans for carrying out the payeeship in the future.
Study: NCT04227990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, doxorubicin, and cyclophosphamide (TAC)
Description: Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.
Study: NCT04276220

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Tenosynovial biopsy
Description: Tenosynovial biopsy taken from the wrist at the carpal tunnel release surgery.
Study: NCT04548089

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC)
Description: Each Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC) will focus on 3 major areas that cultivate self-care, resilience and communal support. The specific intervention structure include: Week 1 - Empowering Self-Care: Introduction to the science of stress, self-care, burnout, as well as the arts and mindfulness to cultivate resilience; Week 2 - Reflective Caregiving: Reflection of caregiving experiences that demonstrates strengths and challenges; Week 3 - Understanding Loss: Introduction to the science of loss, how grief can impair hope and wellbeing, and how self-compassion can help transform suffering into blessings.; Week 4 - Meaning Reconstruction: Reflection on caregiver identities, to elicit the lessons and wisdoms learnt, and to create renewed meaning to sustain their caregiving journeys. Guided mindfulness mediation will also be professionally recorded to form a daily take-home mindfulness mediation exercise for participants, each exercise will last 10-20 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC)
Description: Each Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC) will focus on 3 major areas that cultivate self-care, resilience and communal support. The specific intervention structure include: Week 1 - Empowering Self-Care: Introduction to the science of stress, self-care, burnout, as well as the arts and mindfulness to cultivate resilience; Week 2 - Reflective Caregiving: Reflection of caregiving experiences that demonstrates strengths and challenges; Week 3 - Understanding Loss: Introduction to the science of loss, how grief can impair hope and wellbeing, and how self-compassion can help transform suffering into blessings.; Week 4 - Meaning Reconstruction: Reflection on caregiver identities, to elicit the lessons and wisdoms learnt, and to create renewed meaning to sustain their caregiving journeys. Guided mindfulness mediation will also be professionally recorded to form a daily take-home mindfulness mediation exercise for participants, each exercise will last 10-20 minutes.
Study: NCT02150824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: BI 187004 high dose matching placebo once daily
Study: NCT02926859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol as add-on
Description: Cannabidiol capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo as add-on
Description: Placebo capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks
Study: NCT02458729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid 5%,5ml/amp (intraoperative)
Description: tranexamic acid 1g administered intravenously five minutes before deflation of the tourniquet
Study: NCT03175757

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Turmeric and Black Cumin Seed
Description: Turmeric and Black Cumin Seed formulation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03616275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HRV biofeedback
Description: HRV biofeedback protocol is modified from Lehrer's HRV biofeedback manual (2000), which had been successfully used to improve functioning and quality of life for patients with asthma and COPD. A noninvasive biofeedback system with a NeXus-10 with BioTrace+ (Mind Media B.V., Netherlands) and laptop computer will be used for biofeedback intervention. The intervention protocol is including paced breathing in resonant frequency, abdominal breathing and pursed-lip breathing, and visual biofeedback. The designed intervention protocol will include 8 once-a-week, individual, 20-min in hospital training sessions and twice-a-day, 20-min home self-practices.
Study: NCT02086292

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2 ml 1% Lidocaine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1 ml 2% Lidocaine
Study: NCT02053051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABC4D
Description: Advanced Bolus Calculator for Type 1 Diabetes (ABC4D) to calculate pre-meal insulin boluses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard bolus calculator
Study: NCT02138500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865
Description: Single, oral dose administration of 10 mg PF-06372865 using tablet formulation.
Study: NCT02458729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid 5%,5ml/amp (intraoperative)
Description: tranexamic acid 1g administered intravenously five minutes before deflation of the tourniquet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid 5%,5ml/amp (3 hours after operation)
Description: tranexamic acid 1g administered intravenously 3 hours after operation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline (intraoperative)
Description: 0.9% Normal Saline 20ml administered intravenously five minutes before deflation of the tourniquet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Normal Saline (3 hours after operation)
Description: 0.9% Normal Saline 20ml administered intravenously 3 hours after operation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline (3 hours after operation)
Description: 0.9% Normal Saline 20ml administered intravenously 3 hours after operation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rivaroxaban (10mg)
Description: Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rivaroxaban (10mg)
Description: Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rivaroxaban (10mg)
Description: Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14
Study: NCT02278003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: memory test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: memory test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Study: NCT06261255

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ATT + EMD
Description: All surgical treatments will be performed by the same experienced periodontist (IP) after the administration of local anesthesia. Initially, tooth sectioning of the hopeless tooth (receptor) will be carried out using fissure carbide burs, and the remaining fragments will be extracted as minimally invasively as possible. A tooth-supported surgical guide will be used to prepare the recipient site following the 3D planning. Additional alveoloplasty procedures will be performed with round diamond burs if necessary to adapt the CARP model to the virtual planning position. The donor tooth will be extracted as atraumatically as possible, utilizing a piezoelectric surgical instrument if osteotomy is required, and avoiding the use of elevators or forceps over the root surface. Extraorally, EMD will be applied to the root surface of the donor tooth
Study: NCT02771301

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: dendritic cells
Description: Concurrent of radiotherapy and chemotherapy plus 12 cycles of dendritic cells and cytotoxic lymphocytes treatment
Study: NCT02101463

Intervention type: DEVICE
Group type: OTHER
Intervention: surgeon-modified fenestrated-branched stent-grafts (sm-FBSG)
Study: NCT02875418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUM
Description: STUDY DESIGN~1. Explanation regarding the study and assessing eligibility criteria.~2. Signing an informed consent.~3. Recording of uterine contractions by both EUM and tocodynamometry. A correlation between EUM and tocodynamometry will be calculated. For the purpose of this study, a positive EUM or tocodynamometry will be defined as 3 at least 3 contractions in 30 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tocodynamometry
Description: STUDY DESIGN~1. Explanation regarding the study and assessing eligibility criteria.~2. Signing an informed consent.~3. Recording of uterine contractions by both EUM and tocodynamometry. A correlation between EUM and tocodynamometry will be calculated. For the purpose of this study, a positive EUM or tocodynamometry will be defined as 3 at least 3 contractions in 30 minutes.
Study: NCT00571714

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alpha-2a and ribavirin
Description: Peginterferon alpha-2a 180mcg by subcutaneous injection every week and weight based ribavirin, 800 to 1400mg/day by mouth in two divided doses every day for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alpha-2a , ribavirin and betaine
Description: Peginterferon alpha-2a 180mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400 mg/day by mouth in divided doses twice a day plus betaine 10 gm dissolved in juice twice a day for twelve weeks followed by peginterferon alpha-2a 180 mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400mg/day by mouth in divided doses twice a day for 36 weeks.
Study: NCT04227990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, doxorubicin, and cyclophosphamide (TAC)
Description: Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, doxorubicin, and cyclophosphamide (TAC)
Description: Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.
Study: NCT03061513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ubiquinol
Description: Ubiquinol caplets 600mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT00683410

Intervention type: BIOLOGICAL
Intervention: Pneumococcal Conjugate Vaccine, 7-valent (Prevenar)
Study: NCT00217672

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Patients receive bevacizumab 15 mg/kg intravenously (I.V.) every 3 weeks until disease progression, unacceptable toxicity, or consent withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.
Study: NCT00370799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caudal epidural injection
Description: group 1: Caudal epidural injection local anesthetics only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caudal Epidural Injection with generic Celestone
Description: Group 2. Caudal Epidural Injection local anesthetic with 6mg of non-particulate Celestone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caudal Epidural Injection with Celestone
Description: Group 3. Caudal Epidural Injection with local anesthetic with 6 mg of brand name Celestone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caudal Epidural Injection with DepoMedrol
Description: Group 4. local anesthetic with 40 mg of alcohol-free DepoMedrol
Study: NCT02982213

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Companion Present
Description: A companion will be present during the epidural catheter placement.
Study: NCT01738867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1521498
Description: White HPMC capsule containing 10 mg of GSK1521498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX)
Description: Swedish orange gelatin capsule containing 25mg of NTX or 50mg of NTX

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules to GSK1521498 or NTX